37th EDRN Steering Committee Meeting/EDRN Lung & Upper Aerodigestive Cancers Collaborative Group Meeting Draft Agenda
Tuesday, October 19, 2021
10:00 a.m. to 5:00 p.m. Eastern Daylight Time
Chair: James Herman, MD, University of Pittsburgh Cancer Institute
Co-chair: Steven Dubinett, MD, University of California, Los Angeles
NCI Program Directors : Lynn Sorbara, PhD, and Karl Krueger, PhD, National Cancer Institute
Agenda
| 10:00 a.m. – 5:00 p.m. | Collaborative Group Meetings |
| Moderators: Lynn Sorbara, PhD, Karl Krueger, PhD, National Cancer Institute | |
| 10:00 a.m. – 3:00 p.m. |
Team Projects and Projects Supported with CORE Funds o What was accomplished and what remains to be done o Feasibility of completion o Lessons learned o Recommendations for improvements |
| 10:00 a.m. – 10:30 a.m. |
01: Lung Cancer Screening in a High-Rick Underrepresented Cohort of Low-Income and African Americans Eric Grogan, MD - Vanderbilt University Validating an Integrated Biomarker and Imaging Approach in the Evaluation of Indeterminate Pulmonary Nodules (IPNs) Stephen Deppen, PhD- Vanderbilt University |
| 10:30 a.m. – 10:40 a.m. | Q/A |
| 10:40 a.m. – 11:10 a.m. |
02: Collaborative Studies of Lung Cancer Associated Airway Gene Expression and Plasma markers Marc Lenburg, PhD - Boston University Steven Dubinett, MD, UCLA |
| 11:10 a.m. – 11:20 a.m. | Q/A |
| 11:20 a.m. – 12:00 p.m. |
03: International Collaborations: Failure and Success Harvey Pass, MD – New York University |
| 12:00 p.m. – 12:10 p.m. | Q/A |
| 12:10 p.m. – 12:30 p.m. | Break |
| 12:30 p.m. – 12:50 p.m. |
04: Longitudinal Study with Samples from Israel Louise Showe, PhD – Wistar Institute |
| 12:50 p.m. – 1:00 p.m. | Q/A |
| 1:00 p.m. – 1:20 p.m. |
05: Phase 2 validation of Airway Epithelial Cell TP53 Mutation Biomarker for Lung Cancer Risk James Willey, MD – University of Toledo |
| 1:20 p.m. – 1:30 p.m. | Q/A |
| 1:30 p.m. – 1:50 p.m. |
06: Radiomic Classifiers for Incidental Pulmonary Nodules Matthew Schabath, PhD – Moffitt Cancer Center |
| 1:50 p.m. – 2:00 p.m. | Q/A |
| 2:00 p.m. – 2:20 p.m. | 07: Non-coding RNAs (ncRNAs) as Biomarkers for Early Detection of Non-Small Cell Lung Cancer |
| Feng Jiang, PhD/Sanford Stass, MD, University of Maryland School of Medicine | |
| 2:20 p.m. – 2:30 p.m. | Q/A |
| 2:30 p.m. – 3:00 p.m. |
08: Plasma and Urine Detection of DNA Methylation in Diverse Populations Methylation Marker Detection of Multiple Cancers in ctDNA Jim Herman, MD – University of Pittsburgh |
| 3:00 p.m. – 3:10 p.m. | Q/A |
| 3:10 p.m. – 3:30 p.m. | Session Wrap Up |
| 3:30 p.m. – 3:50 p.m. | Break |
| 3:50 p.m. – 5:00 p.m. |
Discussion of Potential Clinical Utility Trials Moderators: o James Herman, MD, University of Pittsburgh Cancer institute o Steven Dubinett, MD, University of California, Los Angeles |
| 3:50 p.m. – 4:50 p.m. | Discussion focus: Clinical applications and Trial Design |
| 4:50 p.m. – 5:00 p.m. | Wrap-up of this session |
| 5:00 p.m. | Adjourn |